LYMPHOMA

Adcetris is an antibody-drug that targets a type of lymphoma cell called CD30. It is the first treatment approved by the FDA for fighting Hodgkin lymphoma since 1977, and also the first made to specifically treat anaplastic large cell lymphoma.

Adcetris is the first treatment for fighting Hodgkin lymphoma approved by the FDA since 1977, and the first specifically made to treat anaplastic large cell lymphoma. The drug is marketed by Seattle Genetics of Bothell, Wash.

Researchers at the University of Birmingham have discovered that a modified version of Ecstasy (MDMA) may have great cancer-busting potential, fighting off myeloma, lymphoma, and leukemia.

A government advisory panel unanimously approved an experimental drug, Adcetris, from Bothell, WA.-based drug maker, Seattle Genetics, serving as the company's first commercial drug approved by the U.S. Food and Drug Administration.